Zobrazeno 1 - 10
of 156
pro vyhledávání: '"Wen Jin Wu"'
Autor:
Nishant Mohan, Safiat Ayinde, Hanjing Peng, Shraboni Dutta, Yi Shen, Vincent M. Falkowski, Thomas G. Biel, Tongzhong Ju, Wen Jin Wu
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Bispecific T-cell-engaging antibodies are a growing class of therapeutics with numerous molecules being tested in clinical trials and, currently, seven of them have received market approval. They are structurally complex and function as adaptors to r
Externí odkaz:
https://doaj.org/article/dbf1c1fe10a948ab9b2cbafb34182d8c
Publikováno v:
Cancers, Vol 16, Iss 13, p 2367 (2024)
The mechanisms of mAb-induced ADCC have been well established. However, the ADCC bioassays used to quantify mAb-induced ADCC require continued development/refinement to properly assess and compare the potency of newly developed therapeutic mAbs and b
Externí odkaz:
https://doaj.org/article/63d2bda9fda04617b1d0656ba3b39a93
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 14, p 11694 (2023)
Atezolizumab is an immune checkpoint inhibitor (ICI) targeting PD-L1 for treatment of solid malignancies. Immune checkpoints control the immune tolerance, and the adverse events such as hepatotoxicity induced by ICIs are often considered as an immune
Externí odkaz:
https://doaj.org/article/2e8ac4463ec649e5b903e306f2cd4f7e
Autor:
Yukinori Endo, Brady T. Hickerson, Natalia A. Ilyushina, Nishant Mohan, Hanjing Peng, Kazuyo Takeda, Raymond P. Donnelly, Wen Jin Wu
Publikováno v:
Journal of Virus Eradication, Vol 8, Iss 4, Pp 100307- (2022)
Because of rapid emergence and circulation of the SARS-CoV-2 variants, especially Omicron which shows increased transmissibility and resistant to antibodies, there is an urgent need to develop novel therapeutic drugs to treat COVID-19. In this study
Externí odkaz:
https://doaj.org/article/1d7b6943a99e4c21b90be6a868556f19
Autor:
Nishant Mohan, Atul Agrawal, Yi Shen, Katie L. Winarski, Yukinori Endo, Milos Dokmanovic, Deborah Schmiel, Jiwen Zheng, David S. Rotstein, Lorraine C. Pelosof, Wen Jin Wu
Publikováno v:
Pharmaceutics, Vol 14, Iss 7, p 1381 (2022)
We generated two IgG1-like bispecific antibodies (BsAbs) with different molecular formats, symmetrical DVD-Ig and asymmetrical knob-in-hole (KIH), targeting the same antigens, EGFR and PD-L1 (designated as anti-EGFR/PD-L1). We performed the physioche
Externí odkaz:
https://doaj.org/article/58be08b2889c41238320db318c0f3eb4
Autor:
Yukinori Endo, Wen Jin Wu
Publikováno v:
Cancers, Vol 13, Iss 10, p 2331 (2021)
To explore if the tumor microenvironment contributes to the primary resistance of HER2-positive breast cancer cells to T-DM1, we examined whether Matrigel, a basement membrane matrix that provides a three-dimensional (3D) cell culture condition, caus
Externí odkaz:
https://doaj.org/article/8cd3fa4677d14cb99789779aea496858
Autor:
Nishant Mohan, Salman Hosain, Jun Zhao, Yi Shen, Xiao Luo, Jiangsong Jiang, Yukinori Endo, Wen Jin Wu
Publikováno v:
OncoImmunology, Vol 8, Iss 9 (2019)
Immune check point inhibitors targeting programmed cell death protein-1 (PD-1) and its ligand (PD-L1) have shown clinical success in treatment of human malignancies. Triple negative breast cancer (TNBC), which is primarily characterized by high heter
Externí odkaz:
https://doaj.org/article/7656b417095747d3a173b67310cf7cc0
Autor:
Nishant Mohan, Xiao Luo, Yi Shen, Zachary Olson, Atul Agrawal, Yukinori Endo, David S. Rotstein, Lorraine C. Pelosof, Wen Jin Wu
Publikováno v:
Cancers, Vol 13, Iss 5, p 1027 (2021)
Both EGFR and VEGFR2 frequently overexpress in TNBC and cooperate with each other in autocrine and paracrine manner to enhance tumor growth and angiogenesis. Therapeutic mAbs targeting EGFR (cetuximab) and VEGFR2 (ramucirumab) are approved by FDA for
Externí odkaz:
https://doaj.org/article/5c7d8690f13445c4877a65884b253077
Autor:
M. Khair ElZarrad, Partha Mukhopadhyay, Nishant Mohan, Enkui Hao, Milos Dokmanovic, Dianne S. Hirsch, Yi Shen, Pal Pacher, Wen Jin Wu
Publikováno v:
PLoS ONE, Vol 9, Iss 1 (2014)
Externí odkaz:
https://doaj.org/article/64d14883851c4986981fb4ca858d202d
Autor:
Mohan, Nishant, Ayinde, Safiat, Peng, Hanjing, Dutta, Shraboni, Yi Shen, Falkowski, Vincent M., Biel, Thomas G., Tongzhong Ju, Wen Jin Wu
Publikováno v:
Frontiers in Immunology; 2024, p1-15, 15p